CERo Therapeutics Holdings, Inc.
CERO
$0.8899
-$0.0579-6.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 154.12% | 145.68% | 68.85% | 94.63% | 59.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 115.72% | 98.35% | 77.13% | 94.83% | 158.43% |
| Operating Income | -115.72% | -98.35% | -77.13% | -94.83% | -158.43% |
| Income Before Tax | -16.22% | -82.75% | -79.15% | -229.12% | -10,315.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.22% | -66.73% | -56.36% | -156.83% | -969.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.22% | -66.73% | -56.36% | -156.83% | -969.98% |
| EBIT | -115.72% | -98.35% | -77.13% | -94.83% | -158.43% |
| EBITDA | -123.60% | -144.43% | -157.48% | -294.47% | -- |
| EPS Basic | 52.87% | 11.26% | -27.84% | -158.19% | -2,726.73% |
| Normalized Basic EPS | 42.00% | -14.32% | -58.99% | -217.46% | -46,520.99% |
| EPS Diluted | 52.87% | 11.26% | -27.84% | -158.19% | -2,726.73% |
| Normalized Diluted EPS | 42.00% | -14.32% | -58.99% | -217.46% | -46,520.99% |
| Average Basic Shares Outstanding | 503.53% | 73.79% | -30.48% | -52.60% | -62.83% |
| Average Diluted Shares Outstanding | 503.53% | 73.79% | -30.48% | -52.60% | -62.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |